Ford Motor Company

About: Ford Motor Company is a company organization based out in Dearborn, Michigan, United States. It is known for research contribution in the topics: Internal combustion engine & Signal. The organization has 36123 authors who have published 51450 publications receiving 855200 citations. The organization is also known as: Ford Motor & Ford Motor Corporation.

The Effect of Tool–Sheet Interaction on Damage Evolution in Electromagnetic Forming of Aluminum Alloy Sheet

Abstract: A study of the effect of tool-sheet interaction on damage evolution in electromagnetic forming is presented. Free form and conical die experiments were carried out on 1 mm AA5754 sheet. Safe strains beyond the conventional forming limit diagram (FLD) were observed in a narrow, region in the free form experiments, and over a significant region of the part in the conical die experiments. A parametric numerical study was undertaken, that showed that tool-sheet interaction had a significant effect on damage evolution. Metallographic analysis was carried out to quantify damage in the parts and to confirm the numerical results.

Some Percentile Estimators for Weibull Parameters

Abstract: A percentile estimator for the shape parameter of the Weibull distribution, based on the 17th and 97th sample percentiles, is proposed which is asymptotically about 66% efficient when compared with the MLE (maximum likelihood estimator). A two-observation percentile estimator, based on the 40th and 82nd sample percentiles, for the scale parameter when the shape parameter is unknown is asymptotically about 82y0 efficient when compared with the MLE. The 24th and 93rd sample percentiles yield asymptotically about 41ye jointly efficient percentile estimators for both the scale and shape parameters in a class of two-observation percentile estimators when compared with their MLEs. Some other simple percentile estimators for these parameters are also briefly discussed. Finally, asymptotic properties of these estimators are investigated and their application in statistical inference problems is mentioned.

Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies.

Abstract: BACKGROUND Treatments for papulopustular rosacea (PPR) are limited. OBJECTIVE To demonstrate the efficacy and safety of once-daily ivermectin 1% cream in subjects with moderate to severe PPR. METHODS Two identically designed, randomized, double-blind, controlled studies of ivermectin 1% cream (IVM 1%) or vehicle once daily for 12 weeks were conducted in subjects with moderate to severe PPR. Efficacy assessments were Investigator's Global Assessment (IGA) of disease severity and inflammatory lesion counts. Safety assessments included incidence of adverse events (AEs) and local tolerance parameters. Subjects evaluated their rosacea and completed satisfaction and quality of life (QoL) questionnaires. RESULTS In both studies, a greater proportion of subjects in the IVM 1% group achieved treatment success (IGA "clear" or "almost clear"): 38.4% and 40.1% vs 11.6% and 18.8% for vehicle (both P<.001), respectively. Ivermectin was superior to vehicle in terms of reduction from baseline in inflammatory lesion counts (76.0% and 75.0% vs 50.0% for both vehicle groups, respectively). For all endpoints, starting at week 4 and continuing through week 12, IVM 1% was statistically significantly superior (P<.001). Fewer subjects treated by IVM 1% reported dermatologic AEs, and a higher proportion of subjects were observed to have no skin dryness or itching compared to vehicle. Significantly more subjects receiving IVM 1% reported having an "excellent" or "good" improvement, along with an improved QoL. CONCLUSION Ivermectin 1% cream was effective and safe in treating inflammatory lesions of papulopustular rosacea.

Short-Term Treatment With Ranolazine Improves Mechanical Efficiency in Dogs With Chronic Heart Failure

Abstract: The present study assesses whether ranolazine increases left ventricular (LV) function without an increase in myocardial oxygen consumption (MVO2) and thus improves LV mechanical efficiency in dogs with heart failure (HF). Ranolazine did not change MVO2 and LV mechanical efficiency increased (22.4+/-2.8% to 30.9+/-3.4% (P<0.05). In contrast, dobutamine significantly increased MVO2 and did not improve mechanical efficiency. Thus, short-term treatment with ranolazine improved LV function without an increase in MO2, resulting in an increased myocardial mechanical efficiency in dogs with HF.